Bottom line
LABU vs SPXS: the short answer
LABU (Direxion Daily S&P Biotech Bull 3X ETF) and SPXS (Direxion Daily S&P 500(R) Bear 3X ETF) are both etfs.
But LABU is far broader, holding 163 positions to 11 for SPXS, so beyond the top names it adds exposure SPXS doesn't have.
LABU is cheaper at 0.96% vs 1.04% — a difference of $8.00 a year per $10,000 invested.
Over five years, SPXS returned −36.5% a year vs −39.6% for LABU.
Updated Nov 19, 2026
LABU vs SPXS side by side
| LABU | SPXS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.96% | 1.04% |
| Annual cost per $10k | $96 | $104 |
| 10-yr cost on $10k (prospectus) | $1,178 | $1,271 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +78.7% | −41.5% |
| 5-yr return (annualized) | −39.6% | −36.5% |
| 10-yr return (annualized) | −20.8% | −41.3% |
| Best quarter | +161.5% | +51.2% |
| Worst quarter | −67.4% | −51.2% |
| Net assets (fund) | $494.4M | $451.4M |
| Number of holdings | 163 | 11 |
| Portfolio turnover | 107% | % |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LABU | SPXS | Difference |
|---|---|---|---|
| 2025 | +78.7% | −41.5% | +120.3% |
| 2024 | −25.9% | −42.8% | +16.8% |
| 2023 | −13.4% | −45.9% | +32.4% |
| 2022 | −80.3% | +35.8% | −116.1% |
| 2021 | −64.3% | −58.0% | −6.3% |
| 2020 | +74.7% | −70.4% | +145.2% |
| 2019 | +74.6% | −56.6% | +131.3% |
| 2018 | −57.3% | +3.4% | −60.7% |
| 2017 | +148.7% | −44.5% | +193.2% |
| 2016 | −63.0% | −35.9% | −27.1% |
Source: Fund prospectus bar charts
Holdings overlap
7 of LABU's top 25 holdings also appear in SPXS's top 11.
| Holding | LABU | SPXS |
|---|---|---|
| Dreyfus | 15.86% | 35.74% |
| Goldman Financial | 14.83% | 30.50% |
| N/a | 9.63% | -1.98% |
| N/a | 7.30% | -1.98% |
| Goldman Sachs Liq Es Fd A | 5.35% | 10.02% |
| N/a | 4.85% | -1.98% |
| N/a | 3.87% | -1.98% |
Source: SEC Form N-PORT
LABU top 10
- Dreyfus — 15.86%
- Goldman Financial — 14.83%
- N/a — 9.63%
- N/a — 7.30%
- Goldman Sachs Liq Es Fd A — 5.35%
- N/a — 4.85%
- N/a — 3.87%
- Apogee Therapeutics Inc — 1.11%
- Oruka Therapeutics Inc — 1.03%
- Dianthus Therapeutics Inc — 0.96%
SPXS top 10
- Dreyfus — 35.74%
- Goldman Financial — 30.50%
- Dreyfus — 10.31%
- Goldman Sachs Liq Es Fd A — 10.02%
- N/a — -0.11%
- N/a — -0.76%
- N/a — -0.99%
- N/a — -1.51%
- N/a — -1.51%
- N/a — -1.89%
FAQ
What is the difference between LABU and SPXS?
Which is cheaper, LABU or SPXS?
Should I own both LABU and SPXS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.